Physician profile
Debby Thomas
NPI 1790957496
$2,242.60
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,650 · 2022: $90.82 · 2023: $242 · 2024: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $501.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $501.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $501.43 | 2023-2024 | Dysport |
| Biohaven Pharmaceuticals, INC. | $221.69 | 2021 | |
| Collegium Pharmaceutical, INC. | $183.94 | 2021 | |
| Abbvie INC. | $181.86 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $155.53 | 2021 | |
| Medtronic, INC. | $146.47 | 2021-2022 | |
| Amgen INC. | $140.74 | 2021 | |
| Biodelivery Sciences International, INC. | $140.66 | 2021 | |
| Redhill Biopharma INC. | $120.89 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.64 | 2021-2022 | |
| Ibsa Pharma INC. | $69.97 | 2021 | |
| Almatica Pharma LLC | $69.77 | 2021 | |
| Arbor Pharmaceuticals, INC. | $57.55 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $51.54 | 2021 | |
| Currax Pharmaceuticals LLC | $32.60 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $20.18 | 2021 | |
| Daiichi Sankyo INC. | $20.00 | 2021 | |
| Horizon Therapeutics Plc | $15.24 | 2021 | |
| Scilex Pharmaceuticals INC. | $14.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debby Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.